Cargando…

Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis

BACKGROUND: The efficacy and safety of intravenous thrombolysis (IVT) for acute ischemic stroke with atrial fibrillation (AF) is still controversial. METHODS: We conducted a meta-analysis of all relevant studies, retrieved through systematic search of PubMed, Embase, and Cochrane databases up to Dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yunzhen, Ji, Chunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877096/
https://www.ncbi.nlm.nih.gov/pubmed/33573619
http://dx.doi.org/10.1186/s12883-021-02095-x
_version_ 1783650097768169472
author Hu, Yunzhen
Ji, Chunmei
author_facet Hu, Yunzhen
Ji, Chunmei
author_sort Hu, Yunzhen
collection PubMed
description BACKGROUND: The efficacy and safety of intravenous thrombolysis (IVT) for acute ischemic stroke with atrial fibrillation (AF) is still controversial. METHODS: We conducted a meta-analysis of all relevant studies, retrieved through systematic search of PubMed, Embase, and Cochrane databases up to December 31, 2019. Modified Rankin Scale (mRS) scores of 0–1 at 90 days, mRS of 0–2 at 90 days, overall mortality, and incidence of symptomatic intracranial hemorrhage (sICH) were collected as outcome measures. Fixed- and random-effects meta-analytical models were applied, and between-study heterogeneity was assessed. RESULTS: A total of 8509 patients were enrolled in 18 studies. A comparison of IVT treatment in AF versus non-AF patients showed that AF was associated with a significantly lower proportion of patients with mRS of 0–1 (24.1% vs. 34.5%; OR 0.59; 95% CI 0.43–0.81; P < 0.001), mRS of 0–2 (33.6% vs. 47.8%; OR 0.55; 95% CI 0.43–0.70; P < 0.001), as well as significantly higher mortality (19.4% vs. 11.5%; OR 2.05; 95% CI 1.79–2.36; P < 0.001) and higher incidence of sICH (6.4% vs. 4.1%; OR 1.60; 95% CI 1.27–2.01; P < 0.001). A comparison of AF patients who were subjected or not to IVT showed that thrombolysis carried a higher risk of sICH (5.7% vs. 1.6%; OR 3.44; 95% CI 2.04–5.82; P < 0.001) and was not associated with a better prognosis. Subgroup analysis in prospective studies also suggested a poorer functional prognosis and higher mortality in AF patients treated with IVT compared with those who did not receive IVT. Some heterogeneity was present in this meta-analysis. CONCLUSIONS: Acute IS patients with AF had worse outcomes than those without AF after thrombolytic therapy, and had a higher incidence of sICH after thrombolysis than those without thrombolysis. Thrombolysis in ischemic stroke patients with AF should be carefully considered based on clinical factors such as NIHSS score, age, and the type of AF.
format Online
Article
Text
id pubmed-7877096
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78770962021-02-11 Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis Hu, Yunzhen Ji, Chunmei BMC Neurol Research Article BACKGROUND: The efficacy and safety of intravenous thrombolysis (IVT) for acute ischemic stroke with atrial fibrillation (AF) is still controversial. METHODS: We conducted a meta-analysis of all relevant studies, retrieved through systematic search of PubMed, Embase, and Cochrane databases up to December 31, 2019. Modified Rankin Scale (mRS) scores of 0–1 at 90 days, mRS of 0–2 at 90 days, overall mortality, and incidence of symptomatic intracranial hemorrhage (sICH) were collected as outcome measures. Fixed- and random-effects meta-analytical models were applied, and between-study heterogeneity was assessed. RESULTS: A total of 8509 patients were enrolled in 18 studies. A comparison of IVT treatment in AF versus non-AF patients showed that AF was associated with a significantly lower proportion of patients with mRS of 0–1 (24.1% vs. 34.5%; OR 0.59; 95% CI 0.43–0.81; P < 0.001), mRS of 0–2 (33.6% vs. 47.8%; OR 0.55; 95% CI 0.43–0.70; P < 0.001), as well as significantly higher mortality (19.4% vs. 11.5%; OR 2.05; 95% CI 1.79–2.36; P < 0.001) and higher incidence of sICH (6.4% vs. 4.1%; OR 1.60; 95% CI 1.27–2.01; P < 0.001). A comparison of AF patients who were subjected or not to IVT showed that thrombolysis carried a higher risk of sICH (5.7% vs. 1.6%; OR 3.44; 95% CI 2.04–5.82; P < 0.001) and was not associated with a better prognosis. Subgroup analysis in prospective studies also suggested a poorer functional prognosis and higher mortality in AF patients treated with IVT compared with those who did not receive IVT. Some heterogeneity was present in this meta-analysis. CONCLUSIONS: Acute IS patients with AF had worse outcomes than those without AF after thrombolytic therapy, and had a higher incidence of sICH after thrombolysis than those without thrombolysis. Thrombolysis in ischemic stroke patients with AF should be carefully considered based on clinical factors such as NIHSS score, age, and the type of AF. BioMed Central 2021-02-11 /pmc/articles/PMC7877096/ /pubmed/33573619 http://dx.doi.org/10.1186/s12883-021-02095-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Hu, Yunzhen
Ji, Chunmei
Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis
title Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis
title_full Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis
title_fullStr Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis
title_full_unstemmed Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis
title_short Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis
title_sort efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877096/
https://www.ncbi.nlm.nih.gov/pubmed/33573619
http://dx.doi.org/10.1186/s12883-021-02095-x
work_keys_str_mv AT huyunzhen efficacyandsafetyofthrombolysisforacuteischemicstrokewithatrialfibrillationametaanalysis
AT jichunmei efficacyandsafetyofthrombolysisforacuteischemicstrokewithatrialfibrillationametaanalysis